Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 14, 2023

BUY
$1.43 - $3.3 $16,084 - $37,118
11,248 New
11,248 $37,000
Q3 2022

Oct 25, 2022

SELL
$2.55 - $4.42 $765 - $1,326
-300 Reduced 2.55%
11,448 $51,000
Q2 2022

Aug 12, 2022

SELL
$2.71 - $3.6 $766 - $1,018
-283 Reduced 2.35%
11,748 $32,000
Q4 2021

Feb 08, 2022

SELL
$2.81 - $4.23 $1,967 - $2,961
-700 Reduced 5.5%
12,031 $48,000
Q3 2021

Nov 02, 2021

SELL
$3.14 - $4.09 $785 - $1,022
-250 Reduced 1.93%
12,731 $42,000
Q2 2021

Aug 11, 2021

SELL
$3.01 - $4.01 $779 - $1,038
-259 Reduced 1.96%
12,981 $49,000
Q1 2021

May 14, 2021

BUY
$3.46 - $7.88 $4,743 - $10,803
1,371 Added 11.55%
13,240 $51,000
Q4 2020

Feb 12, 2021

BUY
$3.99 - $17.73 $47,357 - $210,437
11,869 New
11,869 $54,000

Others Institutions Holding BCLI

About BRAINSTORM CELL THERAPEUTICS INC.


  • Ticker BCLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,486,200
  • Market Cap $82.8M
  • Description
  • Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...
More about BCLI
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.